Clinical trials are carefully designed research studies that help doctors and scientists evaluate new ways to prevent, diagnose, and treat disease. They may test medications, medical devices, procedures, or lifestyle interventions to determine whether they are safe and effective for people. By following strict scientific and ethical standards, clinical trials provide the evidence needed to improve patient care and expand treatment options.
Participation in a clinical trial is voluntary, and each study follows a detailed plan called a protocol. This protocol outlines who can join, what will happen during the study, how long it will last, and how researchers will monitor safety. Participants are typically informed about the study’s purpose, potential benefits, and possible risks before deciding whether to take part, a process known as informed consent.
Clinical trials play a vital role in advancing medicine and shaping the future of healthcare. They help researchers better understand diseases, compare existing treatments, and develop innovative therapies that may improve outcomes for patients. Whether conducted at hospitals, universities, or research centers, clinical trials contribute to medical progress and offer individuals the opportunity to be part of discoveries that may benefit future generations.
For more information, please contact Blaire Graham at BGraham@prismvisiongroup.com.
results.
A Randomized, Controlled, Partially Masked, Phase 3b Study to Assess the Injection Burden, Efficacy, Safety, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec (ABBV-RGX-314) in a Real-World Context in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)
A Multi-center, Randomized, Double-masked, Active-comparator-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)
A Randomized, Double-masked, Comparative Clinical Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 938 8 mg Versus EYLEA® HD (Aflibercept) Delivered Via Intravitreal Injection in Participants With Neovascular Age-related Macular Degeneration
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneration
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneration
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneration
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneration
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneration
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneration
A Non-Interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (Acp/Izervay™) in Routine Clinical Practice in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
A Non-Interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (Acp/Izervay™) in Routine Clinical Practice in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
A Non-Interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (Acp/Izervay™) in Routine Clinical Practice in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
A Non-Interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (Acp/Izervay™) in Routine Clinical Practice in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
A Non-Interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (Acp/Izervay™) in Routine Clinical Practice in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
A Non-Interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (Acp/Izervay™) in Routine Clinical Practice in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
A Non-Interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (Acp/Izervay™) in Routine Clinical Practice in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
A Phase 1/2 Study to Evaluate the Safety and Efficacy of Intravitreal Administration of BS01, a Recombinant Adeno-Associated Virus Vector Expressing ChronosFP (AAV2-CAGChronosFP) in Patients With Geographic Atrophy Secondary to Dry AMD
Phase 1/2, Safety and Efficacy Trial of BS01, a Recombinant Adeno-Associated Virus Vector Expressing ChronosFP in Patients With Retinitis Pigmentosa
A Randomized Double-masked, Multicenter, 3-arm, Pivotal Phase 2/3 Study to Evaluate the Efficacy and Safety of Intravitreal (IVT) EYE201/MK-8748 Compared to Aflibercept (2 mg) in Participants With Neovascular Age-related Macular Degeneration (NVAMD)
A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS)
A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS)
A Phase IIa, Multicenter, Open-label, Single-Arm Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
A Randomized Trial of Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age
A Randomized Trial of Dichoptic Treatment for Amblyopia in Children 8 to 12 Years of Age
A Randomized, Double Masked, Placebo-controlled, Multicenter, Dose-range Finding Study to Assess the Efficacy and Safety of FWY003 in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration
A Phase 2 Multicenter, Randomized, Double-masked, Sham-controlled, Reference-arm Study to Evaluate Efficacy and Safety of ONL1204 in Patients With Geographic Atrophy (GA) Associated With Age-related Macular Degeneration (AMD)
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Clarifying the Optimal Application of SLT Therapy Trial
About the Clinical Trials Listed on This Site
The clinical trials listed on this site are research studies that are investigating potential new treatments or approaches to care. A trial’s inclusion on this site is for informational purposes only and does not represent a recommendation or endorsement of any specific treatment. Choosing to participate in a clinical trial is voluntary, and participation does not guarantee effectiveness for any individual.
Considering Participation in a Clinical Trial
Taking part in a clinical trial is completely voluntary. Whether or not you choose to participate is a personal decision. We encourage you to discuss any clinical trial you are considering with your physician or healthcare team so they can help you determine whether it may be appropriate for you.
Protecting Your Privacy
If you contact us by email, please do not include personal health information, medical records, or other sensitive information in your message. If additional information is needed, we will provide guidance on how to share it securely.